[68Ga]Ga-Asp2-JR11的合成、临床前评价及临床转化:一种用于神经内分泌肿瘤PET显像的SSTR2拮抗剂
本研究合成并临床前评价了新型SSTR2拮抗剂[68Ga]Ga-Asp2-JR11,并在9例神经内分泌肿瘤患者中完成首次人体PET/CT显像及剂量学评估。该探针较对照物具有更高亲水性、更高 molar activity 和更高肿瘤摄取,在9例患者33个病灶中检出21个[18F]FDG漏诊病灶,肝转移灶SUVmax和靶/本底比值均高于[18F]FDG。
要点
- [68Ga]Ga-Asp2-JR11较[68Ga]Ga-DOTA-TATE和[68Ga]Ga-NOTA-JR11在体外及micro PET/CT中肿瘤摄取更高
- 9例患者33个病灶中,[68Ga]Ga-Asp2-JR11检出21个[18F]FDG漏诊病灶,尤其位于肝脏
- 肝转移灶SUVmax 8.8 vs 3.2(p=0.001),靶/本底比值6.9 vs 2.7(p<0.0001),均为[68Ga]Ga-Asp2-JR11 vs [18F]FDG
核心结论
- [68Ga]Ga-Asp2-JR11是一种新型SSTR2拮抗剂PET探针,较现有探针具有改善的亲水性、受体结合、肿瘤摄取和体内稳定性。
- 其高肿瘤/本底对比度和良好剂量学特征提示其作为临床可转化放射性配体用于NENs灵敏且特异PET显像的潜力。
研究设计与样本
- 合成Asp2-JR11并通过分子对接、体外实验和体内显像评价其结合特性。
- 对Asp2-JR11、NOTA-JR11和DOTA-TATE进行68Ga放射性标记,在AR42J(SSTR2阳性)和HCT116(SSTR2阴性)肿瘤模型中进行细胞摄取、内化、PET/CT显像、生物分布和阻断实验。
- 首次人体研究纳入9例神经内分泌肿瘤患者,行[68Ga]Ga-Asp2-JR11 PET/CT和[18F]FDG PET/CT显像及剂量学评估。
主要发现
- 分子对接显示Asp2-JR11与NOTA-JR11结合能相当,但与SSTR2形成更多氢键(10 vs 5)。
- [68Ga]Ga-Asp2-JR11放射化学纯度>95%,molar activity为12.9-14.8 GBq/µmol,LogD为-3.18±0.01,亲水性高于对照物。
- AR42J细胞中[68Ga]Ga-Asp2-JR11 30分钟摄取为9.95±0.10%AD/10⁶细胞,120分钟内化为17.63±0.91%;体外及micro PET/CT中摄取显著高于[68Ga]Ga-DOTA-TATE和[68Ga]Ga-NOTA-JR11(如30分钟10.67±0.16 vs 7.79±0.50%ID/g,p<0.05)。
- 体内显像和生物分布证实更高的肿瘤/本底比值和更低的靶外器官摄取,尤其肾脏、胰腺和脾脏;共注射SSTR2配体显著抑制肿瘤摄取。
- 9例患者33个病灶中,[68Ga]Ga-Asp2-JR11检出21个[18F]FDG漏诊病灶,尤其位于肝脏;肝转移灶SUVmax 8.8 vs 3.2(p=0.001),靶/本底比值6.9 vs 2.7(p<0.0001),均为[68Ga]Ga-Asp2-JR11 vs [18F]FDG。
关键数值与推荐
- 剂量学显示膀胱壁吸收剂量最高(5.78×10⁻² mSv/MBq),全身有效剂量为9.94×10⁻³ mSv/MBq。
- 人体显像中脾脏呈最高瞬时摄取,肿瘤在注射后12分钟即可清晰显影并维持强对比至120分钟。
- 放射性标记[68Ga]Ga-Asp2-JR11放射化学纯度>95%,molar activity 12.9-14.8 GBq/µmol,LogD -3.18±0.01。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Somatostatin receptor subtype 2 (SSTR2) is overexpressed in well-differentiated neuroendocrine neoplasms (NENs) and serves as a key target for positron emission tomography (PET) imaging. While SSTR2 agonists such as [68Ga]Ga-DOTA-TATE are widely used clinically, recent evidence suggests that antagonist radioligands can bind more receptor sites without inducing internalization, potentially offering superior imaging performance. Here, we report the synthesis, preclinical validation, and pilot clinical translation of [68Ga]Ga-Asp2-JR11, a novel SSTR2 antagonist radioligand featuring an -Asp2-PEG2- linker designed to enhance hydrophilicity and receptor engagement for PET Imaging of NENs. METHODS: Asp2-JR11 was synthesized by modifying the NOTA-JR11 backbone, and its binding properties were evaluated via molecular docking, in vitro assays, and in vivo imaging. Radiolabeling with 68Ga was performed for Asp2-JR11, NOTA-JR11, and DOTA-TATE. We conducted cell uptake, internalization, PET/CT imaging, biodistribution, and blocking studies in AR42J (SSTR2-positive) and HCT116 (SSTR2-negative) tumor models. A first-in-human study included nine patients with NENs who underwent [68Ga]Ga-Asp2-JR11 PET/CT and [18F]FDG PET/CT imaging, along with dosimetry assessment. RESULTS: Docking analysis showed that Asp2-JR11 maintained equivalent binding energy to NOTA-JR11 but formed more hydrogen bonds with SSTR2 (10 vs. 5), suggesting enhanced stability. [68Ga]Ga-Asp2-JR11 demonstrated high radiochemical purity (> 95%), higher molar activity (12.9-14.8 GBq/µmol), and greater hydrophilicity (LogD = - 3.18 ± 0.01) than comparators. In AR42J cells, [68Ga]Ga-Asp2-JR11 exhibited rapid uptake (9.95 ± 0.10%AD/10⁶ cells at 30 min) and low internalization (17.63 ± 0.91% at 120 min), with significantly higher uptake than [68Ga]Ga-DOTA-TATE and [68Ga]Ga-NOTA-JR11 in both in vitro and micro PET/CT studies (e.g., 10.67 ± 0.16 vs. 7.79 ± 0.50%ID/g at 30 min, p < 0.05). In vivo imaging and biodistribution confirmed higher tumor-to-background ratios and reduced off-target organ uptake, notably in the kidneys, pancreas, and spleen. Tumor uptake was significantly inhibited by co-injection of SSTR2 ligands, confirming specificity. In human subjects, [68Ga]Ga-Asp2-JR11 showed favorable biodistribution and rapid clearance via renal excretion, with the spleen showing the highest transient uptake. Tumors were clearly visualized as early as 12 min post-injection and maintained strong contrast up to 120 min. Dosimetry revealed the highest absorbed dose in the urinary bladder wall (5.78 × 10⁻² mSv/MBq), with an effective whole-body dose of 9.94 × 10⁻³ mSv/MBq. Comparative PET/CT imaging in nine patients (33 lesions) showed that [68Ga]Ga-Asp2-JR11 detected 21 lesions missed by [18F]FDG, particularly in the liver. For liver metastases, [68Ga]Ga-Asp2-JR11 yielded higher SUVmax (8.8 vs. 3.2, p = 0.001) and tumor-to-background ratio (6.9 vs. 2.7, p < 0.0001) compared to [18F]FDG. CONCLUSION: [68Ga]Ga-Asp2-JR11, a novel SSTR2 antagonist PET probe, exhibits improved hydrophilicity, receptor engagement, tumor uptake, and in vivo stability compared to existing agents. Its high tumor-to-background contrast and favorable dosimetry profile underscore its potential as a clinically translatable radioligand for sensitive and specific PET imaging of NENs.
引用
- Chen Z, Mu X, Zhang L, et al. Synthesis, preclinical evaluation, and clinical translation of [68Ga]Ga-Asp2-JR11, a SSTR2 antagonist for PET imaging of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2025. PMID: 40883440. doi:10.1007/s00259-025-07474-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。